Malignant pleural mesothelioma: from the bench to the bedside. (Q38019747)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22710421%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Malignant pleural mesothelioma: from the bench to the bedside (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22710421%20AND%20SRC:MED&resulttype=core&format=json

malignant pleural mesothelioma

5 February 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22710421%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

P Astoul

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22710421%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

F Galateau-Salle

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22710421%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

A Scherpereel

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22710421%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

1 reference

15 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22710421%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22710421%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22710421%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22710421%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

481-493

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22710421%20AND%20SRC:MED&resulttype=core&format=json

TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis

5 February 2020

cites work

1 reference

Advances in the biology of malignant pleural mesothelioma

21 January 2018

1 reference

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

21 January 2018

1 reference

The pathogenesis of mesothelioma

21 January 2018

1 reference

Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma

21 January 2018

1 reference

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

21 January 2018

1 reference

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma

21 January 2018

1 reference

Enhancing the apoptotic and therapeutic effects of HDAC inhibitors

21 January 2018

1 reference

Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK.

21 January 2018

1 reference

Functional inactivation of NF2/merlin in human mesothelioma

21 January 2018

1 reference

Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours

21 January 2018

1 reference

Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene.

21 January 2018

1 reference

Markers for the non-invasive diagnosis of mesothelioma: a systematic review

21 January 2018

1 reference

A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.

21 January 2018

1 reference

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma

21 January 2018

1 reference

Advantages of the nested case-control design in diagnostic research

21 January 2018

1 reference

Case-control and two-gate designs in diagnostic accuracy studies

21 January 2018

1 reference

Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond

21 January 2018

1 reference

Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.

21 January 2018

1 reference

PTEN expression is a strong predictor of survival in mesothelioma patients

21 January 2018

1 reference

Validation of genomics-based prognostic tests in malignant pleural mesothelioma

21 January 2018

1 reference

Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer

21 January 2018

1 reference

hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.

21 January 2018

1 reference

Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression

21 January 2018

1 reference

Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors

21 January 2018

1 reference

Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer

21 January 2018

1 reference

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

21 January 2018

1 reference

Expert opinions of the first italian consensus conference on the management of malignant pleural mesothelioma

21 January 2018

1 reference

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

21 January 2018

1 reference

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

21 January 2018

1 reference

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

21 January 2018

1 reference

Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.

21 January 2018

1 reference

Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma

21 January 2018

1 reference

Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma.

21 January 2018

1 reference

Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma

21 January 2018

1 reference

Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody

21 January 2018

1 reference

The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma

21 January 2018

1 reference

Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines

21 January 2018

1 reference

Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention

21 January 2018

1 reference

Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?

21 January 2018

1 reference

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

21 January 2018

1 reference

Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma

21 January 2018

1 reference

Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma

21 January 2018

1 reference

Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention

21 January 2018

1 reference

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines

21 January 2018

1 reference

Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients.

21 January 2018

1 reference

Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos

21 January 2018

1 reference

Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth

21 January 2018

1 reference

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

21 January 2018

1 reference

Antiangiogenic therapies for mesothelioma

21 January 2018

1 reference

Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma

21 January 2018

1 reference

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

21 January 2018

1 reference

A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.

21 January 2018

1 reference

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

21 January 2018

1 reference

Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509

21 January 2018

1 reference

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

21 January 2018

1 reference

Thalidomide in patients with malignant pleural mesothelioma

21 January 2018

1 reference

A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307

21 January 2018

1 reference

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

21 January 2018

1 reference

Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial

21 January 2018

1 reference

Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

21 January 2018

1 reference

Angiogenesis is an independent prognostic factor in malignant mesothelioma

21 January 2018

1 reference

Serum PDGF-AB in pleural mesothelioma

21 January 2018

1 reference

New agents in the management of advanced mesothelioma.

21 January 2018

1 reference

Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders

21 January 2018

1 reference

Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors

21 January 2018

1 reference

Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion

21 January 2018

1 reference

Cellular and molecular parameters of mesothelioma

21 January 2018

1 reference

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma

21 January 2018

1 reference

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

21 January 2018

1 reference

Mesothelin: a new target for immunotherapy

21 January 2018

1 reference

Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy

21 January 2018

1 reference

Biomarkers for malignant pleural mesothelioma: current status

21 January 2018

1 reference

Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts

21 January 2018

1 reference

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma

21 January 2018

1 reference

A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion

21 January 2018

1 reference

Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma

21 January 2018

1 reference

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials

21 January 2018

1 reference

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies

21 January 2018

1 reference

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

21 January 2018

1 reference

Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study

21 January 2018

1 reference

Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors

21 January 2018

1 reference

A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma

21 January 2018

1 reference

New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents

21 January 2018

1 reference

Interleukin-12 induces an effective antitumor response in malignant mesothelioma.

21 January 2018

1 reference

BCL-2 family regulation by the 20S proteasome inhibitor bortezomib

21 January 2018

1 reference

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

21 January 2018

1 reference

Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma

21 January 2018

1 reference

Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)

21 January 2018

1 reference

High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma

21 January 2018

1 reference

Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells

21 January 2018

1 reference

Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses

21 January 2018

1 reference

Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma

21 January 2018

1 reference

Novel intrapleural therapies for malignant diseases

21 January 2018

1 reference

Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.

21 January 2018

1 reference

Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.

21 January 2018

1 reference

Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma.

21 January 2018

1 reference

Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy

21 January 2018

1 reference

A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses

21 January 2018

1 reference

Mesothelin targeted cancer immunotherapy

21 January 2018

1 reference

Listeria-based cancer vaccines that segregate immunogenicity from toxicity

21 January 2018

1 reference

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients

21 January 2018

1 reference

Pathophysiology of the pleura

21 January 2018

1 reference

Soluble Mesothelin–related Peptides in the Diagnosis of Malignant Pleural Mesothelioma

21 January 2018

1 reference

Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000339259

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22710421%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference